Group 1 - The company reported a revenue of 340 million yuan in 2024, a decrease of 6.7%, and a net profit attributable to shareholders of 100 million yuan, down 15.9% [2] - In Q1 2024, the company achieved a revenue of 66 million yuan, a decline of 11.2%, with a net profit of 11 million yuan, down 55.7% [2] - The gross margin improved to 70.4%, an increase of 0.7 percentage points, mainly due to the increased revenue share from surgical power consumables [2] Group 2 - The surgical power device equipment revenue declined significantly due to external factors affecting bidding, while consumables saw steady growth, increasing by 15.69% year-on-year [3] - The company is a leader in the domestic surgical power device market, continuously expanding into endoscopy and energy surgical equipment, aiming to become a comprehensive solution provider for surgical procedures [4] - The market for surgical power devices in China was valued at 7.2 billion yuan in 2022, with a trend towards single-use consumables gradually replacing reusable ones [4] Group 3 - The company expects a compound annual growth rate of 6.9% in net profit attributable to shareholders over the next three years, driven by the replacement of reusable consumables and the introduction of innovative products [5] - The company has made significant breakthroughs in the field of flexible endoscopy, successfully obtaining registration for new medical devices [4]

一、 说明会类型 证券代码：688576 证券简称：西山科技 公告编号：2025-020 重庆西山科技股份有限公司 关于召开 2024 年度暨 2025 年第一季度业绩说明会的 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 五、 联系人及咨询电话 重庆西山科技股份有限公司（以下简称"公司"）于 2025 年 4 月 29 日在上 海证券交易所网站（www.sse.com.cn）披露《2024 年年度报告》《2025 年第一季 度报告》。为便于广大投资者更加全面深入地了解公司经营业绩、发展战略等情 况，公司计划于 2025 年 5 月 16 日（星期五）15:00-16:00 在"价值在线" （www.ir-online.cn）举办重庆西山科技股份有限公司 2024 年度暨 2025 年第一 会议召开时间：2025 年 5 月 16 日（星期五）15:00-16:00 会议召开地点：价值在线（www.ir-online.cn） 会议召开方式：网络互动方式 会 议 问 题 征 集 ： 投 资 者 可 于 ...

来源：金融界 最新一期业绩显示，2025年一季报，公司实现营业收入6587.71万元，同比-11.20%；净利润1147.68万 元，同比-55.66%，销售毛利率67.64%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)74西山科技34.6329.571.6929.18亿行业平均 48.9047.004.53103.78亿行业中值36.4137.242.4046.92亿1天益医疗-1685.63-2887.291.8021.48亿2澳华内 镜-613.48307.694.9164.65亿3诺唯赞-417.99-494.372.2989.45亿4博晖创新-329.61523.043.5248.36亿5爱朋 医疗-325.82247.533.9226.73亿6硕世生物-125.93-1840.221.1336.84亿7奥精医疗-117.01-171.501.5421.72亿 8睿昂基因-98.61-80.961.4012.76亿9康泰医学-84.98-71.803.0355.93亿10中红医疗-67.51-53.850.8546.92亿 11华大智造-63.30-56.174.36337.46亿 5 ...

Revenue Performance - In 2024, the company's operating revenue was 336,380,651.11 yuan, a decrease of 6.74% compared to 2023's 360,689,152.26 yuan, indicating challenges in market expansion and potential market share erosion [1] - The surgical power consumables segment grew steadily, with a year-on-year increase of 15.69%, while the surgical power devices and new product equipment saw revenue declines due to external factors such as delayed bidding [1] - Certain products, like breast biopsy needles, experienced a slight revenue drop due to centralized procurement impacts, although neurosurgery, orthopedics, and ENT consumables showed significant growth exceeding 40% [1] Profitability Analysis - The net profit attributable to shareholders was 98,666,904.12 yuan, down 15.92% from 117,344,082.20 yuan in 2023, influenced by increased R&D expenses and reduced government subsidies [2] - R&D expenses rose to 55,239,983.73 yuan, an 18.79% increase, which compressed profit margins, while government subsidies fell from 14,461,373.20 yuan in 2023 to 4,643,974.74 yuan in 2024 [2] - The non-GAAP net profit decreased by 22.45% to 71,710,314.84 yuan, indicating weakened core business profitability and challenges in enhancing main business earnings [2] Earnings Per Share - Basic earnings per share (EPS) for 2024 was 1.97 yuan, down 22.13% from 2.53 yuan in 2023, directly affecting shareholder returns [3] - The non-GAAP EPS fell by 28.14% to 1.43 yuan, further highlighting the decline in profitability and challenges in operational stability [3] Expense Management - Total expenses remained relatively stable, with sales expenses at 87,641,744.80 yuan, a slight increase of 0.06% from 2023, and management expenses rising by 2.87% to 25,253,817.19 yuan [3] - R&D expenses accounted for 16.42% of operating revenue, up from 12.89% in 2023, reflecting a commitment to innovation despite short-term profit impacts [3] R&D Personnel - The number of R&D personnel increased by 19% to 144, indicating a focus on enhancing R&D capabilities [4] - The educational background of R&D staff includes 7 PhDs, 48 Master's degrees, and 84 Bachelor's degrees, suggesting a need for further optimization to attract high-end talent [4] Cash Flow Analysis - Net cash flow from operating activities decreased by 42.03% to 39,468,869.13 yuan, primarily due to increased expenditures on materials, salaries, taxes, and R&D [5] - Cash flow from investing activities improved significantly to 309,379,187.15 yuan, compared to -1,312,509,545.87 yuan in 2023, indicating effective adjustments in investment strategy [5] - Cash flow from financing activities was -502,774,371.32 yuan, reflecting increased outflows due to share buybacks and dividends, emphasizing a focus on shareholder returns [5]

Core Insights - The company reported a revenue of 336 million yuan and a net profit attributable to shareholders of 98.67 million yuan for the reporting period [1] - The company maintains its strategic positioning as a provider of overall solutions for minimally invasive surgical tools, focusing on business line layout and expansion [1] Financial Performance - Revenue for the reporting period was 336 million yuan, with a net profit of 98.67 million yuan [1] - R&D expenses amounted to 55.24 million yuan, reflecting an 18.79% year-on-year increase [2] R&D Investment - The number of R&D personnel increased by 19% year-on-year, indicating a strong commitment to innovation [2] - R&D investment as a percentage of revenue has grown from 11.42% in 2022 to 16.42% in 2024, demonstrating a consistent increase in focus on R&D [2] Strategic Direction - The company plans to continue its dual growth strategy of "internal development" and "external expansion" while adhering to its strategic positioning [2] - The product strategy will focus on the integration of endoscopic systems, surgical power devices, energy surgical equipment, and other extensions in the minimally invasive surgery field [2]

Core Viewpoint - Xishan Technology (688576) reported a revenue of 336 million yuan and a net profit attributable to shareholders of 98.67 million yuan for 2024, with a basic earnings per share of 1.97 yuan [1] Financial Performance - The company proposed a profit distribution plan of 10 yuan per 10 shares, totaling 45.19 million yuan in cash dividends, which accounts for 45.80% of the net profit for 2024 [1] - The total amount for cash dividends and share buybacks reached 499.5 million yuan, representing 501.81% of the net profit for the period [1] Business Strategy and Market Position - The company maintains its strategic positioning as a "provider of overall solutions for minimally invasive surgical tools," focusing on business line layout and expansion [1] - The company has seen steady growth in surgical power consumables, particularly in neurosurgery, orthopedics, and ENT fields, with consumable revenue increasing by over 40% year-on-year [1] Product Development and R&D Investment - Significant growth was noted in energy surgical equipment, with ultrasound bone knife consumables and plasma device consumables showing remarkable increases, particularly the plasma products which achieved revenue breakthroughs for the first time [2] - The company increased its R&D personnel by 19% and R&D expenses by 18.79%, reaching 55.24 million yuan in 2024 [2] - R&D investment as a percentage of revenue has consistently increased from 11.42% in 2022 to 16.42% in 2024, indicating a strong commitment to innovation [2] Technological Advancements - The company made significant breakthroughs in the field of flexible endoscopes, overcoming core technical bottlenecks in electronic digestive tract flexible endoscopes, with product registration progressing smoothly [2] Future Growth Strategy - The company plans to continue increasing R&D investment, focusing on hospital user development and usage enhancement, while actively expanding into overseas markets [3] - The dual growth strategy of "internal development" and "external expansion" will be pursued, supported by a "innovation-driven" and "capital-driven" approach [3]

证券代码：688576 证券简称：西山科技 公告编号：2025-019 重庆西山科技股份有限公司 关于召开2024年年度股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 2024年年度股东大会 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 （四） 现场会议召开的日期、时间和地点 召开日期时间：2025 年 5 月 21 日 14 点 30 分 召开地点：重庆市两江新区康美街道康竹路 2 号西山科技 B 栋行政楼 6 楼 会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 5 月 21 日 股东大会召开日期：2025年5月21日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 至2025 年 5 月 21 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间 ...

证券代码：688576 证券简称：西山科技 公告编号：2025-015 重庆西山科技股份有限公司 第四届监事会第四次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 重庆西山科技股份有限公司（以下简称"公司"）第四届监事会第四次会议于 2025 年 4 月 28 日 15:30 以现场结合通讯方式在公司会议室召开。应出席会议监 事 3 名，实际出席会议监事 3 名，会议由监事会主席常婧召集和主持。会议通知 于 2025 年 4 月 18 日通过书面方式和电话等方式发出。 本次会议的召开符合《中华人民共和国公司法》（以下简称"《公司法》"） 和《重庆西山科技股份有限公司公司章程》（以下简称"《公司章程》"）的有关 规定。 二、监事会会议审议情况 会议经过审核、表决，通过以下决议： （一）审议通过《关于公司<2024 年度监事会工作报告>的议案》 经审议，监事会认为公司 2024 年度监事会工作报告符合法律、行政法规、 规范性文件和《公司章程》相关规定。因此，监事会一致同意本议案。 表决情况 ...

证券代码：688576 证券简称：西山科技 公告编号：2025-016 重庆西山科技股份有限公司 关于 2024 年度利润分配方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 每股分配比例：拟向全体股东每 10 股派发现金红利人民币 10.00 元（含 税），不进行资本公积金转增股本，不送红股。 截至本公告披露日，公司通过回购专用证券账户所持有本公司股份 1,312,721 股，不参与本次利润分配。 本次利润分配以实施权益分派股权登记日登记的总股本扣除公司回购专 用证券账户股份余额为基数，具体日期将在权益分派实施公告中明确。 在实施权益分派的股权登记日前因可转债转股/回购股份/股权激励授予 股份回购注销/重大资产重组股份回购注销等致使公司应分配股数（总股本扣除 公司回购专用证券账户股份余额）发生变动的，拟维持每股分配比例不变，相应 调整分配总额，并将另行公告具体调整情况。 本次利润分配方案已经公司第四届董事会第四次会议、第四届监事会第 四次会议审议通过，尚需提交公司 2024 年年度股东大会审议， ...

Financial Performance - The basic earnings per share for 2024 is 1.9700 yuan, a decrease of 22.13% compared to 2023's 2.5300 yuan [1] - The net profit for 2024 is 0.99 billion yuan, down 15.38% from 1.17 billion yuan in 2023 [1] - The return on equity (ROE) for 2024 is 4.93%, a significant decline of 46.06% from 9.14% in 2023 [1] - The total revenue for 2024 is 3.36 billion yuan, a decrease of 6.93% from 3.61 billion yuan in 2023 [1] - The net asset per share is 35.57 yuan, down 12.75% from 40.77 yuan in 2023 [1] Shareholder Structure - The top ten unrestricted shareholders hold a total of 764.16 million shares, accounting for 29.99% of the circulating shares, with an increase of 187.62 million shares compared to the previous period [1] - China Pharmaceutical Investment Co., Ltd. has newly entered the top shareholders with 194.78 million shares, representing 7.65% of the total share capital [2] - Suzhou Jinhui Phase II Equity Investment Partnership holds 153.75 million shares, a 76.51% increase [2] - Shanghai Hongfu Private Fund Management Co., Ltd. remains unchanged with 138.31 million shares [2] - Shanghai Guanyu Investment Development Co., Ltd. has exited the top ten shareholders, previously holding 44.74 million shares [2] Dividend Distribution - The company has announced a dividend distribution plan of 10 yuan per share (including tax) [3]